Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment.

PloS one - 1 Jan 2018

Jabbarzadeh Kaboli Parham, Ismail Patimah, Ling King-Hwa

Abstract excerpt

RAF kinases are a family of enzymes in the MAP kinase pathway that contribute to the development of different types of cancer. BRAF is the most important member of RAF kinases. BRAF mutations have been detected in 7% of all cancers and 66% of melanomas; as such, the FDA has approved a few BRAF inhibitor drugs to date. However, BRAF can activate CRAF leading to resistance to BRAF inhibitors. Berberine (BBR) is an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Molecular Docking Simulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasms

Share to Protein Binding

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins c-raf

Share to raf Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 29565994
DOI: 10.1371/journal.pone.0193941
PMCID: PMC5863970

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment.PMID 29565994Read ↗

Pharmacophore and binding analysis of known and novel B-RAF kinase inhibitors.Semantic proximity Read ↗

In silico evaluation of selected triterpenes as potential inhibitors of BRAF and BRAFV600E kinases for cancer treatment.Semantic proximity Read ↗

An updated literature on BRAF inhibitors (2018-2023).Semantic proximity Read ↗

In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.Semantic proximity Read ↗

On the development of B-Raf inhibitors acting through innovative mechanisms.Semantic proximity Read ↗

On the development of B-Raf inhibitors acting through innovative mechanismsSemantic proximity Read ↗

Recent advances in B-RAF inhibitors as anticancer agents.Semantic proximity Read ↗

Design, synthesis, and biological evaluation of new B-RafV600E kinase inhibitors.Semantic proximity Read ↗

Mutant B-Raf Kinase Inhibitors as Anticancer Agents.Semantic proximity Read ↗

Molecular Modeling Unveils the Effective Interaction of B-RAF Inhibitors with Rare B-RAF Insertion Variants.Semantic proximity Read ↗

High-throughput virtual screening and preclinical analysis identifies CB-1, a novel potent dual B-Raf/c-Raf inhibitor, effective against wild and mutant variants of B-Raf expression in colorectal carcinoma.Semantic proximity Read ↗

A combined 3D-QSAR and molecular docking strategy to understand the binding mechanism of (V600E)B-RAF inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.